Verrica Pharmaceuticals Inc
VRCA5.738USD
+0.098+1.74%
交易中 （美東）報價延遲15分鐘
526.73M總市值
虧損本益比TTM
關於 Verrica Pharmaceuticals Inc 公司
Verrica Pharmaceuticals Inc. 是一家皮膚病治療公司。該公司專注於開發和商業化皮膚病治療方法。其產品線包括三種候選產品：YCANTH、VP-315 和 VP-103。YCANTH 是一種專有的藥物-設備組合，包含 GMP 控制的斑蝥素配方。我們還在開發 YCANTH，用於治療普通疣和外生殖器疣的潛在後續適應症。此外，該公司還在開發 YCANTH，用於治療外生殖器疣或外生殖器疣 EGW。其第二種候選產品 VP-315 是一種基於溶瘤肽的注射療法，可用於治療皮膚腫瘤疾病，包括基底細胞癌、非轉移性黑色素瘤和非轉移性默克爾細胞癌。VP-103 是第二種基於斑蝥素的藥物設備組合，可用於治療蹠疣。
公司簡介
公司代碼VRCA
公司名稱Verrica Pharmaceuticals Inc
上市日期Jun 15, 2018
CEODr. Jayson Rieger
員工數量71
證券類型Ordinary Share
年結日Jun 15
公司地址44 West Gay Street
城市WEST CHESTER
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編19380
電話14844533300
網址https://verrica.com/
公司代碼VRCA
上市日期Jun 15, 2018
CEODr. Jayson Rieger
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
88.99K
+50.90%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
11.00K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Mr. John J. Kirby
Mr. John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
Interim Chief Financial Officer, Interim Principal Financial Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Mr. Mark A. Prygocki, Sr.
Mr. Mark A. Prygocki, Sr.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
88.99K
+50.90%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
11.00K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Manning (Paul B.)
53.85%
Caligan Partners, LP
9.72%
Armistice Capital LLC
9.26%
BKB Growth Investments LLC
6.46%
Boothbay Fund Management, LLC
3.04%
Other
17.67%
持股股東
持股股東
佔比
Manning (Paul B.)
53.85%
Caligan Partners, LP
9.72%
Armistice Capital LLC
9.26%
BKB Growth Investments LLC
6.46%
Boothbay Fund Management, LLC
3.04%
Other
17.67%
股東類型
持股股東
佔比
Individual Investor
57.67%
Hedge Fund
19.53%
Investment Advisor
6.74%
Corporation
6.74%
Investment Advisor/Hedge Fund
5.58%
Research Firm
0.28%
Venture Capital
0.06%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
3.35%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
182
8.94M
96.65%
+3.24M
2025Q1
194
69.94M
75.99%
+19.16M
2024Q4
191
70.39M
77.72%
+35.42M
2024Q3
179
29.67M
67.28%
-5.27M
2024Q2
173
33.68M
79.75%
-1.13M
2024Q1
171
34.51M
82.01%
-2.46M
2023Q4
170
35.04M
83.66%
+1.56M
2023Q3
172
32.74M
78.91%
-2.85M
2023Q2
169
31.35M
77.69%
+2.98M
2023Q1
171
29.74M
73.94%
+2.67M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Manning (Paul B.)
31.38M
33.93%
+17.53M
+126.54%
Nov 26, 2024
Caligan Partners, LP
8.99M
9.72%
+1.56M
+21.04%
Mar 31, 2025
Armistice Capital LLC
8.57M
9.26%
-353.60K
-3.96%
Mar 31, 2025
BKB Growth Investments LLC
5.98M
6.46%
+5.98M
--
Nov 22, 2024
Boothbay Fund Management, LLC
2.81M
3.04%
+220.30K
+8.52%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
2.55%
+481.41K
+25.61%
Mar 31, 2025
Stalfort (John A)
1.87M
2.03%
+238.09K
+14.56%
Apr 01, 2025
BlackRock Institutional Trust Company, N.A.
1.12M
1.22%
+32.58K
+2.98%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.02M
1.1%
+541.22K
+113.40%
Mar 31, 2025
Rieger (Jayson)
889.88K
0.96%
+300.19K
+50.91%
Apr 01, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Simplify Propel Opportunities ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
Simplify Propel Opportunities ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
